464 related articles for article (PubMed ID: 22943413)
1. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors.
Sharma M; Gupta M; Singh D; Kumar M; Kaur P
Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, evaluation and molecular docking of prolyl-fluoropyrrolidine derivatives as dipeptidyl peptidase IV inhibitors.
Sharma M; Gupta M; Singh D; Kumar M; Kaur P
Chem Biol Drug Des; 2013 Aug; 82(2):156-66. PubMed ID: 23581745
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of thiouracil derivatives as dipeptidyl peptidase IV inhibitors.
Sharma M; Singh D; Gupta M
Chem Biol Drug Des; 2013 Feb; 81(2):257-64. PubMed ID: 23039850
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors.
Liu Y; Si M; Tang L; Shangguan S; Wu H; Li J; Wu P; Ma X; Liu T; Hu Y
Bioorg Med Chem; 2013 Sep; 21(18):5679-87. PubMed ID: 23938053
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors.
Zhang L; Su M; Li J; Ji X; Wang J; Li Z; Li J; Liu H
Chem Biol Drug Des; 2013 Feb; 81(2):198-207. PubMed ID: 22994702
[TBL] [Abstract][Full Text] [Related]
6. Identification of dipeptidyl peptidase IV inhibitors: virtual screening, synthesis and biological evaluation.
Xing J; Li Q; Zhang S; Liu H; Zhao L; Cheng H; Zhang Y; Zhou J; Zhang H
Chem Biol Drug Des; 2014 Sep; 84(3):364-77. PubMed ID: 24674599
[TBL] [Abstract][Full Text] [Related]
7. Discovering novel α-aminoacyl-containing proline derivatives with potent and selective inhibitory activity against dipeptidyl peptidase IV: design, synthesis, biological evaluation, and molecular modeling.
Zhang X; Wang J; Su M; Li Z; Li J; Li J; Liu H
Chem Biol Drug Des; 2012 Dec; 80(6):843-52. PubMed ID: 22726613
[TBL] [Abstract][Full Text] [Related]
8. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
[TBL] [Abstract][Full Text] [Related]
9. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
Deng X; Han L; Zhou J; Zhang H; Li Q
Bioorg Chem; 2017 Dec; 75():357-367. PubMed ID: 29096096
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.
Wu D; Jin F; Lu W; Zhu J; Li C; Wang W; Tang Y; Jiang H; Huang J; Liu G; Li J
Chem Biol Drug Des; 2012 Jun; 79(6):897-906. PubMed ID: 22381062
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, biological screening, and molecular docking studies of piperazine-derived constrained inhibitors of DPP-IV for the treatment of type 2 diabetes.
Kushwaha RN; Srivastava R; Mishra A; Rawat AK; Srivastava AK; Haq W; Katti SB
Chem Biol Drug Des; 2015 Apr; 85(4):439-46. PubMed ID: 25216392
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
Patel BD; Bhadada SV; Ghate MD
Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors.
Li Q; Han L; Zhang B; Zhou J; Zhang H
Org Biomol Chem; 2016 Oct; 14(40):9598-9611. PubMed ID: 27714283
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
Nabeno M; Akahoshi F; Kishida H; Miyaguchi I; Tanaka Y; Ishii S; Kadowaki T
Biochem Biophys Res Commun; 2013 May; 434(2):191-6. PubMed ID: 23501107
[TBL] [Abstract][Full Text] [Related]
16. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
[TBL] [Abstract][Full Text] [Related]
18. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
19. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
[TBL] [Abstract][Full Text] [Related]
20. Structural optimization of pyrazolo[1,5-a]pyrimidine derivatives as potent and highly selective DPP-4 inhibitors.
Shen J; Deng X; Sun R; Tavallaie MS; Wang J; Cai Q; Lam C; Lei S; Fu L; Jiang F
Eur J Med Chem; 2020 Dec; 208():112850. PubMed ID: 32987315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
